| Identification | Back Directory | [Name]
Escitalopram Impurity | [CAS]
1363421-46-8 | [Synonyms]
MOMIPP
(E)-3-(5-Methoxy-2-methyl-1H-indol-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one
inhibit,Inhibitor,JNK1/2,BBB,Fab1,c-Jun,MOMIPP,Bcl-2,PIKfyve,Macropinocytosis,Bcl-xL | [Molecular Formula]
C18H16N2O2 | [MDL Number]
MFCD34476008 | [MOL File]
1363421-46-8.mol | [Molecular Weight]
292.33 |
| Chemical Properties | Back Directory | [Boiling point ]
521.0±50.0 °C(Predicted) | [density ]
1.239±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 31.25 mg/mL (106.90 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [pka]
16.05±0.30(Predicted) | [color ]
Yellow to orange |
| Hazard Information | Back Directory | [Uses]
MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP penetrates the blood-brain barrier (BBB)[1][2]. | [in vivo]
MOMIPP (80 mg/kg; i.p.; once daily; for 15 consecutive days) shows moderately effective in suppressing progression of intracerebral glioblastoma xenografts[2]. | Animal Model: | Athymic CrTac:NCR-Foxn1 mice (female, 7-8?weeks)[2] | | Dosage: | 80?mg/kg
| | Administration: | i.p.; once daily; for 15 consecutive days | | Result: | Suppressed progression of intracerebral glioblastoma xenografts. |
| [References]
[1] Margaux Colin, et al. Dysregulation of Macropinocytosis Processes in Glioblastomas May Be Exploited to Increase Intracellular Anti-Cancer Drug Levels: The Example of Temozolomide. Cancers (Basel). 2019 Mar 22;11(3):411. DOI:10.3390/cancers11030411
[2] Zehui Li, et al. The JNK signaling pathway plays a key role in methuosis (non-apoptotic cell death) induced by MOMIPP in glioblastoma. BMC Cancer. 2019 Jan 16;19(1):77. DOI:10.1186/s12885-019-5288-y |
|
|